Bicycle Therapeutics, a biotechnology company headquartered in Cambridge, has appointed Alethia Young as its new chief financial officer.

Young joins Bicycle on July 17 from Graphite Bio, where she works as CFO, and previously served as senior biotech analyst and head of research at Cantor Fitzgerald.

Kevin Lee, chief executive officer of Bicycle Therapeutics, said: “We are thrilled to welcome Alethia to Bicycle and believe her experience and insights will make her an invaluable addition to our team.

“Alethia is a seasoned expert in the biopharma industry, with her leadership position at Graphite and decade-plus of experience as a top biotech research analyst making her the ideal appointment as we continue to advance our clinical trials, prepare for commercialisation and head into our next phase of growth as a company.

“On behalf of our board and the entire team at Bicycle, I want to thank Lee Kalowski for his contributions to the company. Lee, who served as Bicycle’s chief financial officer since 2017, was instrumental in his work leading the company through its IPO and subsequent fundraisings, putting Bicycle in a strong financial position for our future.”

Young has more than 20 years of experience in the healthcare and biotech industry.

Prior to joining Graphite Bio as CFO, she served as senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies.

BioTech Bicycle Therapeutics appoints Chief Medical Officer 

Before joining Cantor Fitzgerald in 2018, she held senior biotech analyst positions at Credit Suisse and Deutsche Bank.

Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors.

She began her career at J.P Morgan in the investment banking and asset management divisions. She earned a B.A. in economics and Spanish from Duke University.

Young said: “I have been following the Bicycle story since covering them as a research analyst on the sell-side, and have been especially impressed by the recent clinical progress the team has made across their platform.

“I look forward to working alongside the team to help patients in need of new treatment options, by moving forward the entire pipeline and expanding the potential applications of the Bicycle platform across oncology and beyond.”

In addition, Bicycle announced the promotion of Travis Thompson, senior vice president, finance, to senior vice president, chief accounting officer.

Thompson will work alongside Young, overseeing the company’s financial and accounting operations.

Bicycle Therapeutics  was founded in 2009 and is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

BioTech firm Bicycle Therapeutics makes key appointment

Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilise their structural geometry.